AU2019394972B2 - Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof - Google Patents

Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

Info

Publication number
AU2019394972B2
AU2019394972B2 AU2019394972A AU2019394972A AU2019394972B2 AU 2019394972 B2 AU2019394972 B2 AU 2019394972B2 AU 2019394972 A AU2019394972 A AU 2019394972A AU 2019394972 A AU2019394972 A AU 2019394972A AU 2019394972 B2 AU2019394972 B2 AU 2019394972B2
Authority
AU
Australia
Prior art keywords
seq
substrate
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019394972A
Other languages
English (en)
Other versions
AU2019394972A1 (en
Inventor
Olga Vasiljeva
Michael B. Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytomx Therapeutics Inc
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of AU2019394972A1 publication Critical patent/AU2019394972A1/en
Application granted granted Critical
Publication of AU2019394972B2 publication Critical patent/AU2019394972B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2019394972A 2018-12-06 2019-12-05 Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof Active AU2019394972B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862776409P 2018-12-06 2018-12-06
US62/776,409 2018-12-06
US201862778062P 2018-12-11 2018-12-11
US62/778,062 2018-12-11
PCT/US2019/064779 WO2020118109A2 (en) 2018-12-06 2019-12-05 Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2026202578A Division AU2026202578A1 (en) 2018-12-06 2026-04-07 Matrix Metalloprotease-Cleavable And Serine Or Cysteine Protease-Cleavable Substrates And Methods Of Use Thereof
AU2026202575A Division AU2026202575A1 (en) 2018-12-06 2026-04-07 Matrix Metalloprotease-Cleavable And Serine Or Cysteine Protease-Cleavable Substrates And Methods Of Use Thereof

Publications (2)

Publication Number Publication Date
AU2019394972A1 AU2019394972A1 (en) 2021-06-03
AU2019394972B2 true AU2019394972B2 (en) 2026-01-08

Family

ID=69024693

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019394972A Active AU2019394972B2 (en) 2018-12-06 2019-12-05 Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

Country Status (14)

Country Link
US (3) US12049505B2 (enExample)
EP (1) EP3890764A2 (enExample)
JP (3) JP2022512124A (enExample)
CN (2) CN113271956B (enExample)
AU (1) AU2019394972B2 (enExample)
BR (1) BR112021010433A2 (enExample)
CA (1) CA3120327A1 (enExample)
IL (1) IL283756A (enExample)
MX (1) MX2021006429A (enExample)
MY (1) MY205459A (enExample)
SG (1) SG11202105476XA (enExample)
TW (2) TWI902404B (enExample)
WO (1) WO2020118109A2 (enExample)
ZA (1) ZA202405610B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ718283A (en) 2013-09-25 2022-05-27 Cytomx Therapeutics Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
US9562073B2 (en) 2014-01-31 2017-02-07 Cytomx Therapeutics, Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CA3120327A1 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
WO2020251878A1 (en) * 2019-06-11 2020-12-17 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
CN110702669A (zh) * 2019-09-19 2020-01-17 湖北科益药业股份有限公司 一种快速阿昔洛韦凝胶含量测定的方法
WO2021207669A1 (en) 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4631977A3 (en) * 2020-08-11 2025-12-10 Janux Therapeutics, Inc. Cleavable linker compositions and methods
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
IL311971A (en) 2021-10-08 2024-06-01 Cytomx Therapeutics Inc Activatable cytokine constructs and related compositions and methods
TW202334185A (zh) 2021-10-08 2023-09-01 美商Ｃｙｔｏｍｘ生物製藥公司 可經活化之細胞介素構築體和組合方法
US20250333539A1 (en) 2022-03-23 2025-10-30 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
JP2025512798A (ja) 2022-03-25 2025-04-22 サイトムエックス セラピューティクス，インク． 活性化可能な二重アンカー型マスク化分子及びその使用方法
EP4504782A2 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
EP4260907A1 (en) * 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
AR130078A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Substratos escindibles por proteasas, y métodos de uso de los mismos
JP2025525867A (ja) 2022-08-01 2025-08-07 サイトムエックス セラピューティクス，インク． プロテアーゼ切断性部分及びその使用方法
EP4565250A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
JP2025525868A (ja) 2022-08-01 2025-08-07 サイトムエックス セラピューティクス，インク． プロテアーゼ切断性部分及びその使用方法
JP2025525880A (ja) 2022-08-01 2025-08-07 サイトムエックス セラピューティクス，インク． プロテアーゼ切断性部分及びその使用方法
CN120936384A (zh) 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4695281A1 (en) 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
WO2026035650A2 (en) 2024-08-05 2026-02-12 Cytomx Therapeutics, Inc. Cleavable polypeptides and methods of use thereof

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023409A2 (en) * 1999-09-27 2001-04-05 Human Genome Sciences, Inc. 38 human secreted proteins
WO2001034769A2 (en) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002006481A1 (fr) * 2000-07-14 2002-01-24 Japan Science And Technology Corporation Cible d'un agent anticancereux
EP1262562A2 (en) * 2001-05-30 2002-12-04 The Kitasato Institute Actinomycetes polynucleotides
WO2003027246A2 (en) * 2001-09-24 2003-04-03 Novo Nordisk A/S Antagonists
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
JP2003339385A (ja) * 2002-05-29 2003-12-02 Toyobo Co Ltd 新規３−ヒドロキシ酪酸脱水素酵素遺伝子、新規３−ヒドロキシ酪酸脱水素酵素の製造法、ならびに、新規３−ヒドロキシ酪酸脱水素酵素を用いたケトン体の測定方法および測定用組成物
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US20040123343A1 (en) * 2000-04-19 2004-06-24 La Rosa Thomas J. Rice nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20040216190A1 (en) * 2003-04-28 2004-10-28 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2006100449A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
WO2010025964A1 (en) * 2008-09-08 2010-03-11 Glaxosmithkline Biologicals S.A. Vaccine comprising protein nmbo964 from meisseria meningitidis
WO2011036297A2 (de) * 2009-09-27 2011-03-31 Ruhr-Universität-Bochum Verfahren zur therapie und diagnose von morbus alzheimer
WO2012058606A1 (en) * 2010-10-28 2012-05-03 Joule Unlimited Technologies, Inc. Methods and compositions for the recombinant biosynthesis of terminal olefins
WO2012066059A2 (de) * 2010-11-17 2012-05-24 Basf Se Verfahren zur biokatalytischen cyclisierung von terpenen und darin einsetzbare cyclase-mutanten
WO2013138522A2 (en) * 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20140273089A1 (en) * 2013-03-14 2014-09-18 Amgen, Inc. Fibroblast Growth Factor Receptor-Like Molecules and Uses Thereof
WO2014169336A1 (en) * 2013-04-16 2014-10-23 Commonwealth Scientific And Industrial Research Organisation G protein coupled receptor libraries
WO2014200910A2 (en) * 2013-06-10 2014-12-18 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US20150329881A1 (en) * 2014-05-14 2015-11-19 Samsung Electronics Co., Ltd. Microorganism having novel acrylic acid synthesis pathway and method of producing acrylic acid by using the microorganism
WO2016118629A1 (en) * 2015-01-20 2016-07-28 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
KR20160107038A (ko) * 2015-03-03 2016-09-13 경남대학교 산학협력단 마이오신 아형을 분석하는 방법
WO2017117425A1 (en) * 2015-12-31 2017-07-06 Synthetic Genomics, Inc. Expression of type i fatty acid synthase genes in eukaryotic algae
WO2017218573A1 (en) * 2016-06-16 2017-12-21 The Regents Of The University Of California Methods and compositions for detecting a target rna
CN107723311A (zh) * 2017-11-28 2018-02-23 中国科学院遗传与发育生物学研究所 一种与植物种子粒重相关的TaCKX2‑3D蛋白及其编码基因与应用
WO2018148848A1 (en) * 2017-02-17 2018-08-23 Hyasynth Biologicals Inc. Method and cell line for production of phytocannabinoids and phytocannabinoid analogues in yeast
WO2019161251A1 (en) * 2018-02-15 2019-08-22 The Broad Institute, Inc. Cell data recorders and uses thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
AR007087A1 (es) 1996-05-10 1999-10-13 Danisco Una codificacion de fragmento de adn aislado para una enzima que posee actividad de alfa-glucuronidasa, fragmento de adn correspondiente, vectorrecombinante que tiene insertada dicha codificacion de fragmento de adn, celula huesped transformada con dicho vector recombinante, metodo para producir alfa-
AUPO930697A0 (en) 1997-09-19 1997-10-09 Walter And Eliza Hall Institute Of Medical Research, The Catalytic antibodies and a method of producing same
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
ES2299244T3 (es) 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
WO2000024756A1 (en) 1998-10-23 2000-05-04 Human Genome Sciences, Inc. Fibroblast growth factor receptor-5
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
WO2001055301A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
AU2001280464A1 (en) 2000-08-04 2002-02-18 Eli Lilly And Company C1q-related factor, homologous polypeptides and therapeutic uses thereof
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
WO2002030460A2 (en) 2000-10-09 2002-04-18 Isis Innovation Ltd. Therapeutic antibodies
AU2002230630A1 (en) 2000-11-08 2002-05-21 Beth Israel Deaconess Medical Center, Inc. Methods for determining protease cleavage site motifs
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
AU2002315525A1 (en) 2001-07-03 2003-01-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
US7439319B2 (en) 2001-09-14 2008-10-21 Burnham Institute For Medical Research Selective substrates for matrix metalloproteinases
WO2003038083A1 (en) 2001-10-29 2003-05-08 Bayer Healthcare Ag Regulation of human type i adenylate cyclase
CN101044154A (zh) 2002-02-14 2007-09-26 威廉·J·鲁特 治疗宿主中切割的嵌合分子
US20060009840A1 (en) * 2002-03-15 2006-01-12 Hossainy Syed F Carrier for releasing a therapeutic substance in response to the presence of an enzyme
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
WO2004099254A2 (en) 2003-05-06 2004-11-18 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Activation of recombinant diphtheria toxin fusion proteins by specific proteases highly expressed on the surface of tumor cells
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US9079936B2 (en) 2003-07-01 2015-07-14 University Of Maryland, Baltimore Derivatives of APF and methods of use
WO2005090393A2 (en) 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
CA2592249C (en) 2004-12-20 2014-07-29 Amgen Fremont Inc. Binding proteins specific for human matriptase
EP1865981A2 (en) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e in cancer diagnosis, detection and treatment
AU2006284651C1 (en) 2005-08-31 2013-09-12 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
JP5219819B2 (ja) 2005-10-21 2013-06-26 カタリスト・バイオサイエンシーズ・インコーポレイテッド 補体活性化を阻害する修飾プロテアーゼ
JP2009529522A (ja) 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
US20130332133A1 (en) * 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
BRPI0717638A2 (pt) 2006-10-27 2013-11-12 Genentech Inc Anticorpors e imunoconjugados e usos para os mesmos
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
WO2010088691A2 (en) 2009-02-02 2010-08-05 Washington State University Compositions and methods for treating or preventing conditions and diseases associated with mannheimia haemolytica
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
US20120157824A1 (en) 2009-09-02 2012-06-21 Nanoscale Corporation Mri and optical assays for proteases
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US20110214205A1 (en) 2010-02-26 2011-09-01 Monsanto Technology Llc. Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits
EP2650003B1 (en) 2010-05-20 2016-07-27 Allergan, Inc. Degradable clostridial toxins
GB201009271D0 (en) * 2010-06-02 2010-07-21 Promar As Compositions
PL391627A1 (pl) 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CA2836338C (en) 2011-05-16 2022-05-03 Koninklijke Philips N.V. Tetrazine derivatives used in bio-orthogonal drug activation
US20140193342A1 (en) * 2011-06-10 2014-07-10 The Regents Of The University Of California Enzyme directed assembly of particle theranostics
AU2012275295B2 (en) 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
CN110078827A (zh) 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
EP2863948B1 (en) 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CN105008918A (zh) 2013-01-04 2015-10-28 西托姆克斯治疗公司 用于检测生物系统中的蛋白酶活性的组合物和方法
EP2988786A4 (en) 2013-04-22 2016-12-21 Avelas Biosciences Inc COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE
WO2014193973A2 (en) 2013-05-28 2014-12-04 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
KR20160018579A (ko) 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
WO2014202616A2 (en) 2013-06-19 2014-12-24 Dsm Ip Assets B.V. Rasamsonia gene and use thereof
NZ718283A (en) * 2013-09-25 2022-05-27 Cytomx Therapeutics Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
US9562073B2 (en) * 2014-01-31 2017-02-07 Cytomx Therapeutics, Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CA2984892A1 (en) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
CN107709356A (zh) 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2018071672A1 (en) 2016-10-12 2018-04-19 The Regents Of The University Of Colorado Novel engineered and chimeric nucleases
WO2020077267A1 (en) 2018-10-11 2020-04-16 Northwestern University Biomarker of chronic kidney disease in liver transplant recipients
CA3120327A1 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
WO2001023409A2 (en) * 1999-09-27 2001-04-05 Human Genome Sciences, Inc. 38 human secreted proteins
WO2001034769A2 (en) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
US20040123343A1 (en) * 2000-04-19 2004-06-24 La Rosa Thomas J. Rice nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2002006481A1 (fr) * 2000-07-14 2002-01-24 Japan Science And Technology Corporation Cible d'un agent anticancereux
EP1262562A2 (en) * 2001-05-30 2002-12-04 The Kitasato Institute Actinomycetes polynucleotides
WO2003027246A2 (en) * 2001-09-24 2003-04-03 Novo Nordisk A/S Antagonists
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
JP2003339385A (ja) * 2002-05-29 2003-12-02 Toyobo Co Ltd 新規３−ヒドロキシ酪酸脱水素酵素遺伝子、新規３−ヒドロキシ酪酸脱水素酵素の製造法、ならびに、新規３−ヒドロキシ酪酸脱水素酵素を用いたケトン体の測定方法および測定用組成物
US20040216190A1 (en) * 2003-04-28 2004-10-28 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2006100449A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
WO2010025964A1 (en) * 2008-09-08 2010-03-11 Glaxosmithkline Biologicals S.A. Vaccine comprising protein nmbo964 from meisseria meningitidis
WO2011036297A2 (de) * 2009-09-27 2011-03-31 Ruhr-Universität-Bochum Verfahren zur therapie und diagnose von morbus alzheimer
WO2012058606A1 (en) * 2010-10-28 2012-05-03 Joule Unlimited Technologies, Inc. Methods and compositions for the recombinant biosynthesis of terminal olefins
WO2012066059A2 (de) * 2010-11-17 2012-05-24 Basf Se Verfahren zur biokatalytischen cyclisierung von terpenen und darin einsetzbare cyclase-mutanten
WO2013138522A2 (en) * 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20140273089A1 (en) * 2013-03-14 2014-09-18 Amgen, Inc. Fibroblast Growth Factor Receptor-Like Molecules and Uses Thereof
WO2014169336A1 (en) * 2013-04-16 2014-10-23 Commonwealth Scientific And Industrial Research Organisation G protein coupled receptor libraries
WO2014200910A2 (en) * 2013-06-10 2014-12-18 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US20150329881A1 (en) * 2014-05-14 2015-11-19 Samsung Electronics Co., Ltd. Microorganism having novel acrylic acid synthesis pathway and method of producing acrylic acid by using the microorganism
WO2016118629A1 (en) * 2015-01-20 2016-07-28 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
KR20160107038A (ko) * 2015-03-03 2016-09-13 경남대학교 산학협력단 마이오신 아형을 분석하는 방법
WO2017117425A1 (en) * 2015-12-31 2017-07-06 Synthetic Genomics, Inc. Expression of type i fatty acid synthase genes in eukaryotic algae
WO2017218573A1 (en) * 2016-06-16 2017-12-21 The Regents Of The University Of California Methods and compositions for detecting a target rna
WO2018148848A1 (en) * 2017-02-17 2018-08-23 Hyasynth Biologicals Inc. Method and cell line for production of phytocannabinoids and phytocannabinoid analogues in yeast
CN107723311A (zh) * 2017-11-28 2018-02-23 中国科学院遗传与发育生物学研究所 一种与植物种子粒重相关的TaCKX2‑3D蛋白及其编码基因与应用
WO2019161251A1 (en) * 2018-02-15 2019-08-22 The Broad Institute, Inc. Cell data recorders and uses thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Uncharacterized protein from Saprolegnia diclina", 7 June 2017 (2017-06-07), XP055674716, Retrieved from the Internet <URL:https://www.uniprot.org/uniprot/T0RF53.txt?version=15> [retrieved on 20200309] *
GenBank AAK23786, hypothetical protein CC_1810 [Caulobacter vibrioides CB15], entry date 31 January 2014 *
GenBank ABV27395, hypothetical protein YS_M60-F11.029 [Chloracidobacterium thermophilum], entry date 26 July 2016 *
I-JU CHEN ET AL: "Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains", SCIENTIFIC REPORTS, vol. 7, no. 1, 14 September 2017 (2017-09-14) *
MICHEL, S. L. J. et al., "Selective RNA Binding by a Single CCCH Zinc-Binding Domain from Nup475 (Tristetraprolin)", Biochemistry (2003), Vol 42(16), pages 4626-4630 *
MUSKAN KUKREJA: "The high throughput multiplexed peptide-centric profiling illustrates both the substrate cleavage redundancy and specificity in the MMP family", CHEM BIOL, vol. 22, no. 8, 20 August 2015 (2015-08-20), pages 1122 - 1133 *
P DURRENS: "Clavispora lusitaniae hypothetical protein", 15 June 2017 (2017-06-15), XP055665684, Retrieved from the Internet <URL:https://www.ebi.ac.uk/ena/browser/api/embl/OVF07168.1?lineLimit=1000> [retrieved on 20200206] *
UniProt A0A0D8BN56, Oshone, R. et al., 'Permanent Draft Genome Sequences for Two Variants of Frankia sp. Strain Cpl1, the First Frankia Strain Isolated from Root Nodules of Comptonia peregrina', 2016, [online] [retrieved Jun. 13, 2023] *

Also Published As

Publication number Publication date
SG11202105476XA (en) 2021-06-29
WO2020118109A2 (en) 2020-06-11
JP2022512124A (ja) 2022-02-02
EP3890764A2 (en) 2021-10-13
WO2020118109A3 (en) 2020-08-13
US20250011439A1 (en) 2025-01-09
JP2025172835A (ja) 2025-11-26
JP2025063090A (ja) 2025-04-15
US20200377602A1 (en) 2020-12-03
IL283756A (en) 2021-07-29
TWI902404B (zh) 2025-10-21
AU2019394972A1 (en) 2021-06-03
ZA202405610B (en) 2024-11-27
CA3120327A1 (en) 2020-06-11
MY205459A (en) 2024-10-22
TW202039561A (zh) 2020-11-01
BR112021010433A2 (pt) 2021-08-24
TWI855012B (zh) 2024-09-11
TW202448959A (zh) 2024-12-16
KR20210102318A (ko) 2021-08-19
US20240239904A1 (en) 2024-07-18
CN113271956B (zh) 2025-04-29
US12570748B2 (en) 2026-03-10
JP7781254B2 (ja) 2025-12-05
CN120248140A (zh) 2025-07-04
MX2021006429A (es) 2021-07-15
US12049505B2 (en) 2024-07-30
CN113271956A (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
US12570748B2 (en) Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
AU2023254931B2 (en) Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
US11884746B2 (en) Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
US12459999B2 (en) Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof